Are We Ready for Maternal Respiratory Syncytial Virus Vaccination?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Efficacy of monoclonal antibodies and maternal vaccination for prophylaxis of respiratory syncytial virus disease.Communications medicine · 2025
   Article
2. Maternal vaccination against RSV can substantially reduce childhood mortality in low-income and middle-income countries: A mathematical modeling study.Vaccine: X · 2023
   Article
3. Respiratory Syncytial Virus Infection: Treatments and Clinical Management.Vaccines · 2023
   Review
4. RSV disease in infants and young children: Can we see a brighter future?Human vaccines & immunotherapeutics · 2022
   Article

Corrections and comments

• Comment on
  A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.2022
• Comment on
  Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine.2022

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as